Thursday, April 30, 2020

Who owns Remdesivir ? How much Does is Cost and How much can they make ?

The Remdesivir drug was originally developed for Ebola but has shown promise with COVID-19.

Earlier on Wednesday, Some reported on some clinical test data that offered good, if ambiguous, news about treating COVID-19. within the study, participants treated with a drug called remdesivir recovered on the average 30 percent quicker than those receiving a placebo. But who owns the drug, what proportion of it are often made, and what does it cost?

To answer the primary question, remdesivir is owned by Gilead Sciences, a US biotechnology company. Gilead got its first patent for the drug in 2017 when the corporate was originally targeting it as a possible treatment for the Ebola virus . that did not pan out, but as our earlier article explains, biochemical similarities in how the Ebola and SARS-CoV-2 viruses function led Gilead to ascertain if remdesivir might be repurposed for treating COVID-19. Gilead's patents mean that it's a monopoly on the drug within the us , so barring government intervention or Gilead licensing the patent to others, it is the only company which will manufacture it until 2037, at which point a generic version might be possible.

First little bit of success from a randomized trial of a COVID-19 treatment 
To answer the second question, Gilead announced in April that it had ramped up production of remdesivir at its factory in La Verne, California, in January, and by the start of April, it had already stockpiled enough to treat 140,000 patients, each over the course of 10 days. the corporate also said that it plans to supply enough remdesivir to treat 500,000 patients by October and 1,000,000 patients by the top of 2020. (This explains why there was some outcry in March when it had been revealed that Gilead had applied for something called "orphan drug status" for remdesivir, which is meant to be reserved for rare diseases. Gilead withdrew that application.)
Finally, there's the question of what proportion which will cost. As of today, we do not skills much Gilead intends to charge for remdesivir within the US or elsewhere. In CEO Daniel O'Day's April letter that exposed the prevailing stockpile, he wrote that the corporate "is providing everything of this existing supply at no cost, to treat patients with the foremost severe symptoms of COVID-19. The 1.5 million individual doses are available for compassionate use, expanded access, and clinical trials and can be donated for broader distribution following any potential future regulatory authorizations."

A recent study published within the Journal of Virus Eradication attempts to research the value of producing remdesivir. The authors checked out the chemical synthesis of the drug and concluded that a 10-day course for one person would cost $9, allowing 20 percent losses during formulation, plus the value of the vials, a margin of profit , and tax. However, whether it costs Gilead that to truly produce the drug is unknown, and one needn't be a scholar of the US healthcare system to be skeptical that a completely unique treatment would find yourself being quite so cheap.